Bart Rijnders, MD, PhD

Erasmus MC University Medical Center
Rotterdam, Zuid-Holland, Netherlands

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• 754 - Olorofim for treatment of invasive fungal infections (IFI) due to moulds in patients with limited or no treatment options: Interim results from a Phase 2b open-label study (NCT03583164, Study 32)

  Thursday, October 20, 2022
  2:30 PM - 2:45 PM US ET